OXFORD, England, November 21 /PRNewswire/ -- Oxford Genome Sciences (UK) Ltd "OGeS" announces today that Christopher Hibberd, currently CEO at Astute Medical, Inc. and formerly Senior Vice President Corporate Development at Biosite Incorporated, has joined its Board of Directors.
Christopher Hibberd brings over 15 years of experience in business strategy and corporate development to OGeS. Hibberd is currently working as CEO of Astute Medical, Inc. and prior to that worked for 10 years at Biosite, as SVP Corporate Development, where he was responsible for the identification and pursuit of strategic business opportunities including mergers, acquisitions, partnerships and alliances as well as for developing long-range strategic plans. Prior to joining Biosite, Hibberd was manager at the Boston Consulting Group and was responsible for leading international consultants and client case teams in developing and implementing value-creating strategies for businesses in a variety of industry sectors. Prior to that he held consulting positions at various companies and also was a development engineer for Albright & Wilson Americas from 1987 to 1990.
Hibberd received a chemical engineering degree from the University of Toronto, Canada and earned a master's degree in business administration from the University of Western Ontario, Canada.
"I am very pleased to welcome Christopher to OGeS' Board of Directors. I am confident that his broad expertise will be valuable to support OGeS' corporate development at a time when we are transitioning from target discovery to building our own product pipeline of therapeutic antibodies", commented Dr Christian Rohlff, CEO of OGeS.
"Today's announcement also highlights the excellent working relationship that we developed with Christopher when he was at Biosite, our partner for the development of diagnostics for cancer based on our unique OGAP(R) protein database," he added.
Christopher Hibberd, commenting
|SOURCE Oxford Genome Sciences|
Copyright©2007 PR Newswire.
All rights reserved